REGEN-COV (Casirivimab with Imdevimab) Infusion Treatment
MAHEC has received a supply of the new COVID-19 monoclonal antibody treatment. This treatment may lessen the severity of illness in high risk, mild to moderately ill people infected with COVID-19 and reduce hospitalizations.
Information about REGEN-COV (casirivimab with imdevimab) can be reviewed in the following fact sheets:
- PHE fact sheet for healthcare providers - fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of REGEN-COV (CASIRIVIMAB WITH IMDEVIMAB)
- PHE fact sheet for patients and caregivers - fact Sheet for Patients, Parents and Caregivers: Emergency Use Authorization (EUA) of REGEN-COV (CASIRIVIMAB WITH IMDEVIMAB) for Coronavirus Disease 2019 (COVID-19)
- What to expect during your treatment at MAHEC - this fact sheet will answer many questions patients may have.
Patients must be referred for treatment by a healthcare provider.
MAHEC will only be able to administer to patients 12 years and older who are in first 10 days of symptoms at time of treatment.
Internal referrals can be made by sending a patient message to FM Acute Care Infusion.
External referrals can be made by filling out the referral form located here.
Infusions will take place on the MAHEC Biltmore campus Monday through Friday.
All patients will be contacted by phone the day of or the day prior to infusion AND the day after infusion.
All patients will be encouraged to see their primary care provider by telehealth within 3-7 days of the infusion treatment. Patients who do not have a primary care provider will be referred to MAHEC Internal Medicine for a follow up visit by telehealth.
Patient treatment criteria:
REGEN-COV (casirivimab with imdevimab) is a treatment option for people with documented COVID-19 infection who meet at least one of the following high-risk criteria:
- 65 years of age and older
- Adults with BMI > 25, OR children ages 12-17 who have BMI ≥ 85th percentile for their age and gender based on CDC growth charts
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease or hypertension
- Chronic lung diseases
- Current smoker
- Substance use disorders
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID 19)